These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 31236364)
1. The efficacy and safety of besifloxacin for acute bacterial conjunctivitis: a Meta-analysis. Wang JJ; Gao XY; Li HZ; Du SS Int J Ophthalmol; 2019; 12(6):1027-1036. PubMed ID: 31236364 [TBL] [Abstract][Full Text] [Related]
2. Treating with besifloxacin for acute bacterial conjunctivitis: a Meta-analysis. Wang JJ; Gao XY; Li HZ; Du SS Int J Ophthalmol; 2019; 12(12):1898-1907. PubMed ID: 31850176 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% in children and adolescents with bacterial conjunctivitis: a post hoc, subgroup analysis of three randomized, double-masked, parallel-group, multicenter clinical trials. Comstock TL; Paterno MR; Usner DW; Pichichero ME Paediatr Drugs; 2010 Apr; 12(2):105-12. PubMed ID: 20218747 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis: a multicenter, randomized, double-masked, vehicle-controlled, parallel-group study in adults and children. Silverstein BE; Allaire C; Bateman KM; Gearinger LS; Morris TW; Comstock TL Clin Ther; 2011 Jan; 33(1):13-26. PubMed ID: 21397770 [TBL] [Abstract][Full Text] [Related]
6. The role of besifloxacin in the treatment of bacterial conjunctivitis. Mahvan TD; Hornecker JR; Buckley WA; Clark S Ann Pharmacother; 2014 May; 48(5):616-25. PubMed ID: 24566460 [TBL] [Abstract][Full Text] [Related]
7. Besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis in adults and children. DeLeon J; Silverstein BE; Allaire C; Gearinger LS; Bateman KM; Morris TW; Comstock TL Clin Drug Investig; 2012 May; 32(5):303-17. PubMed ID: 22420526 [TBL] [Abstract][Full Text] [Related]
8. Besifloxacin Ophthalmic Suspension 0.6% Compared with Gatifloxacin Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis in Neonates. Sanfilippo CM; Allaire CM; DeCory HH Drugs R D; 2017 Mar; 17(1):167-175. PubMed ID: 28078599 [TBL] [Abstract][Full Text] [Related]
9. Clinical and Antibacterial Efficacy and Safety of Besifloxacin Ophthalmic Suspension Compared With Moxifloxacin Ophthalmic Solution. Garg P; Mathur U; Sony P; Tandon R; Morris TW; Comstock TL Asia Pac J Ophthalmol (Phila); 2015; 4(3):140-5. PubMed ID: 26065499 [TBL] [Abstract][Full Text] [Related]
10. Besifloxacin: a topical fluoroquinolone for the treatment of bacterial conjunctivitis. Chang MH; Fung HB Clin Ther; 2010 Mar; 32(3):454-71. PubMed ID: 20399984 [TBL] [Abstract][Full Text] [Related]
11. Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: A multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety study. Karpecki P; Depaolis M; Hunter JA; White EM; Rigel L; Brunner LS; Usner DW; Paterno MR; Comstock TL Clin Ther; 2009 Mar; 31(3):514-26. PubMed ID: 19393842 [TBL] [Abstract][Full Text] [Related]
12. Safety and tolerability of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis: data from six clinical and phase I safety studies. Comstock TL; Paterno MR; Decory HH; Usner DW Clin Drug Investig; 2010; 30(10):675-85. PubMed ID: 20629472 [TBL] [Abstract][Full Text] [Related]
13. Besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis patients with Pseudomonas aeruginosa infections. Silverstein BE; Morris TW; Gearinger LS; Decory HH; Comstock TL Clin Ophthalmol; 2012; 6():1987-96. PubMed ID: 23233796 [TBL] [Abstract][Full Text] [Related]
14. Phase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis. Tepedino ME; Heller WH; Usner DW; Brunner LS; Morris TW; Haas W; Paterno MR; Comstock TL Curr Med Res Opin; 2009 May; 25(5):1159-69. PubMed ID: 19323612 [TBL] [Abstract][Full Text] [Related]
16. Besifloxacin: Efficacy and Safety in Treatment and Prevention of Ocular Bacterial Infections. Mah FS; Sanfilippo CM Ophthalmol Ther; 2016 Jun; 5(1):1-20. PubMed ID: 27010720 [TBL] [Abstract][Full Text] [Related]